ROSALIND ADVISORS INC
Q2 2024 Form 13-F
TORONTO, ONTARIO, CANADA
CIK 0001622627
· Institutional investment manager
$130.0M Reported Value Total
Reported value
$130.0M
Quarter over quarter
-10.3%
Holdings
35
Top-10 concentration
59.8%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Steven Salamon
President, Rosalind Advisors, Inc.
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | July 12, 2024 |
| Form | 13F-HR |
| Reported value | $130.0M |
| Positions | 35 |
| Change in reported value | +21.4% |
| New positions | 5 |
| Exited positions | 1 |
| Position turnover | 16.7% |
| Top-10 concentration | 59.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
35 | $311.9M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
29 | $269.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
32 | $248.9M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
29 | $284.5M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
29 | $292.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $210.9M |
|
Q1 2025 13F
Filed May 14, 2025
|
31 | $205.6M |
|
Q4 2024 13F
Filed Feb 11, 2025
|
28 | $195.6M |
|
Q3 2024 13F
Filed Oct 30, 2024
|
29 | $156.2M |
|
Q2 2024 13F
Filed Jul 12, 2024
|
35 | $130.0M |
|
Q1 2024 13F
Filed Apr 25, 2024
|
31 | $107.0M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
27 | $121.4M |
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | DCTH DELCATH SYSTEMS, INC. | $15.5M | 11.95% |
| 2 | MYO MYOMO INC | $8.6M | 6.58% |
| 3 | MDWD MEDIWOUND LTD | $8.0M | 6.13% |
| 4 | OPTN OPTINOSE INC | $7.8M | 6.04% |
| 5 | ABEO ABEONA THERAPEUTICS-NEW | $7.4M | 5.71% |
| 6 | XERS XERIS BIOPHARMA HLDGS INC | $7.0M | 5.4% |
| 7 | CLRB CELLECTAR BIOSCIENCES INC | $6.8M | 5.2% |
| 8 | NSPR INSPIREMD INC | $6.3M | 4.83% |
| 9 | CYBN CYBIN INC | $5.2M | 4.02% |
| 10 | OCUL Ocular Therapeutix, Inc | $5.1M | 3.95% |
| 11 | ABVX ABIVAX SA | $5.0M | 3.85% |
| 12 | PROF PROFOUND MEDICAL CORP | $4.5M | 3.44% |
| 13 | CMPS COMPASS PATHWAYS PLC | $4.4M | 3.41% |
| 14 | TRVI TREVI THERAPEUTICS INC | $4.1M | 3.19% |
| 15 | KALV KALVISTA PHARMACEUTICALS INC | $4.0M | 3.06% |
| 16 | VRDN VIRIDIAN THERAPEUTICS INC | $3.9M | 3.0% |
| 17 | VRNA VERONA PHARMA PLC | $3.6M | 2.78% |
| 18 | CLSD CLEARSIDE BIOMEDICAL INC | $3.4M | 2.59% |
| 19 | OTLK OUTLOOK THERAPEUTICS INC | $3.3M | 2.56% |
| 20 | VERU VERU INC | $2.3M | 1.75% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.